Sante Capital Fund’s Amicus Therapeutics FOLD Stock Holding History

Sante Capital Fund’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-367,187	Closed	-$3.54M	–	60
2021 Q2	$3.54M	Buy	+367,187	New	+$3.58M	1.46%	10

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sante Capital Fund's FOLD Position: Q3 2021 in Review

Sante Capital Fund sold out of Amicus Therapeutics (FOLD) in Q3 2021, closing a stake of 367,187 shares — an estimated $3.54M sold.

Sante Capital Fund first reported a position in FOLD in Q2 2021 and held it in 1 quarter. The position peaked at $3.54M in Q2 2021. 236 funds tracked by Wall St. Rank hold FOLD as of Q3 2021.

Sante Capital Fund reported no remaining Amicus Therapeutics position as of Q3 2021 after selling out during the quarter.
Sante Capital Fund sold 367,187 Amicus Therapeutics shares in Q3 2021, an estimated $3.54M.
Sante Capital Fund first reported a position in Amicus Therapeutics in Q2 2021 and held it in 1 quarter.
Sante Capital Fund's Amicus Therapeutics position peaked at $3.54M in Q2 2021.
236 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2021.

Based on Sante Capital Fund's 13F filing for Q3 2021, filed 15 Nov 2021.